These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17186837)

  • 1. Better ways to target pain.
    Stix G
    Sci Am; 2007 Jan; 296(1):84-6, 88. PubMed ID: 17186837
    [No Abstract]   [Full Text] [Related]  

  • 2. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 3. The NSAID roller coaster: more about rofecoxib.
    Aronson JK
    Br J Clin Pharmacol; 2006 Sep; 62(3):257-9. PubMed ID: 16934039
    [No Abstract]   [Full Text] [Related]  

  • 4. Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?
    Romanovsky AA
    Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1098-9. PubMed ID: 15821282
    [No Abstract]   [Full Text] [Related]  

  • 5. Rofecoxib and clinically significant gastrointestinal events.
    Bombardier C; Laine L; Day R; Hawkey CJ; Hochberg MC; Schnitzer TJ
    Am J Med Sci; 2011 Nov; 342(5):438-9. PubMed ID: 22030845
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to the Vioxx debacle.
    Knudsen JF; Sokol GH
    Am J Med; 2006 Jan; 119(1):93-4. PubMed ID: 16431207
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective inhibition of prostacyclin synthase activity by rofecoxib.
    Griffoni C; Spisni E; Strillacci A; Toni M; Bachschmid MM; Tomasi V
    J Cell Mol Med; 2007; 11(2):327-38. PubMed ID: 17488481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedicine. Back to an aspirin a day?
    Vane JR
    Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462
    [No Abstract]   [Full Text] [Related]  

  • 11. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 12. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
    Wang M; Song WL; Cheng Y; Fitzgerald GA
    J Intern Med; 2008 May; 263(5):500-5. PubMed ID: 18410593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat.
    García-Hernández L; Déciga-Campos M; Guevara-López U; López-Muñoz FJ
    Pharmacol Biochem Behav; 2007; 87(3):331-40. PubMed ID: 17570478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibitors.
    Hawkey CJ
    Lancet; 1999 Jan; 353(9149):307-14. PubMed ID: 9929039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 17. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
    Cahana A; Mauron A
    J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
    [No Abstract]   [Full Text] [Related]  

  • 18. Concern about one drug or entire class of drugs.
    Curković B
    Reumatizam; 2005; 52(1):5-6. PubMed ID: 16689104
    [No Abstract]   [Full Text] [Related]  

  • 19. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition.
    Frölich S; Olliges A; Kern N; Schreiber Y; Narumiya S; Nüsing RM
    Am J Physiol Renal Physiol; 2012 Jul; 303(2):F209-19. PubMed ID: 22573380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitors: no pain, no heart gain?
    Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.